COMMUNIQUÉS West-GlobeNewswire

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
30/09/2025
ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia. ODM-105 (tasipimidine) was [...]
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
30/09/2025
STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
30/09/2025
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo [...]

Pages